ARTIMPLANT AB´s year-end results, January 1 - December 31, 2003

ARTIMPLANT AB's year-end results, January 1 - December 31, 2003 FDA-CLEARANCE AND DRASTICALLY REDUCED LOSSES · Artimplant's net sales for the full year 2003 reached SEK 1.2 million (0.2) · Losses after tax was SEK 30.2 million (61.1) · The result per share was SEK -1.21 (-6.06) · Artimplant's ArtelonTM Surgical Suture got FDA-clearance · An extraordinary shareholders meeting decided on a rights issue and a mandate for a directed share issue · The rights issue was oversubscribed, and yielded close to SEK 48 million Important events after the end of the period: · Artimplant's ARTELON Surgical Suture was approved for marketing in Europe through a CE-mark · The pilot study of accelerated rehabilitation with ARTELON Augmentation Device ACL showed good results · A directed share issue in January 2004 yielded over SEK 14 million Forthcoming financial reports: Annual general meeting in Artimplant's office: April 26, 2004, 5:00 p.m. January-March 2004 report: April 27, 2004 January-June 2004 report: August 27, 2004 January-September 2004 report: November 5, 2004 Financial reports are available at simultaneously with distribution to the media. Artimplant's annual report will be published on the above site March 26, at 12:00 noon. For more information, contact: Tord Lendau, CEO, +46 31 746 5600, +46 708 369 403, Jonas Ström, CFO, +46 31 746 5654, +46 703 016 854, ARTIMPLANT Artimplant's mission is to develop novel degradable materials and implants that meet the needs of patients, physicians and healthcare providers in orthopedics and other therapy areas, the company will work with global partners as a center of excellence in this development. Artimplant's vision is to become the partner of choice in biomaterials for hard and soft tissue repair in multiple therapy areas. The Artimplant share is listed on the Stockholm stock exchange's O list. ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report The full report

About Us

Artimplant is a research- and development company, active within bio-materials.